covid treatment

Histogen (HSTO.Q), and its partner Amerimmune, today announced top-line results from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy….
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research…
It would seem the race to find a suitable treatment for COVID-19 is over, as Gilead Sciences (GILD.Q) announced today that their antiviral drug Veklury (remdesivir) received the nod…
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions….
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions….
Doing what we do at Equity Guru, every day, we receive emails and dms from shareholders of different companies – all expressing their grievances. Disgruntled with various issues such…